Technology | September 15, 2009

FDA Clears New EnSite Velocity Cardiac Mapping System

September 15, 2009 – St. Jude Medical Inc. said yesterday the U.S. Food and Drug Administration (FDA) cleared and U.S. launch of the EnSite Velocity Cardiac Mapping System, which is designed to help physicians more efficiently diagnose and guide therapy to treat abnormal heart rhythms.

Advancements in the design of the EnSite Velocity System increase procedural efficiency and speed, making it easier to use from set-up and operation, to clinical application, the company said. With new hardware and software, the system offers simple set-up and connections, an intuitive software interface and includes two key new capabilities, the OneMap tool and RealReview function. The OneMap tool enables physicians to create a detailed cardiac model and electrical map together using multiple catheters and electrodes, allowing physicians to collect and display more relevant patient information in a shorter amount of time. The RealReview function provides real-time, side-by-side views of the live procedure and previously recorded portions of the procedure. This feature gives physicians a quick and easy comparison of events and results at different times throughout the procedure, without losing the ability to visualize and navigate catheters in real-time. The EnSite Velocity System is an open platform, which means that it is compatible with essentially all diagnostic and ablation catheters, recording systems and energy sources used for ablation procedures.

“We have been using the EnSite System for nearly 10 years because of its ability to display and map electrical signals from multiple catheters and electrodes, and its convenience of being an open platform,” said Walid Saliba, M.D., of the Cleveland Clinic Foundation in Cleveland, Ohio. “The next-generation EnSite Velocity System also allows us to treat patients with any arrhythmia and navigate the heart with potential reduction in procedural time.”

St. Jude said the system helps reduce fluoroscopy exposure and is the only mapping system capable of supporting both contact and noncontact mapping.

“This system has exceptionally detailed chamber models and clear electroanatomical maps,” said Javier Sanchez, M.D., of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas. “Compared to other systems, I found the user interface to be very intuitive, quick and easy to learn.”

The EnSite Velocity System is used in minimally invasive electrophysiology procedures. Catheters with electrodes are inserted into a cardiac chamber; these electrodes are then located or visualized by the system, which records electrical information from the heart and displays it in a three-dimensional anatomical model. These highly detailed anatomical models, or maps, enable physicians to diagnose and guide therapy for abnormal heart rhythms. Like previous models of the EnSite System, the EnSite Velocity System allows catheter navigation to occur with reduced fluoroscopy, thus reducing potential for risks associated with excessive exposure to X-rays.

For more information: www.sjm.com

Related Content

 ElectroSonix
News | EP Lab | December 30, 2019
December 30, 2019 — Acoustoelectric cardiac imaging, a new, noninvasive cardiac imaging technology developed at the U
Peter_Weiss, M.D., explains a Stereotaxis robotically navigated cardiac ablation procedure at Banner University Medicine Heart Institute.

Peter_Weiss, M.D., explains a Stereotaxis robotically navigated cardiac ablation procedure at Banner University Medicine Heart Institute.

Feature | EP Lab | December 23, 2019 | J. Peter Weiss, M.D., MSc
Robotic technology, which helps carry out repetitive tasks efficiently and precisely, has been gaining ground in...
Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins. The future of CRM device technology.

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.

Feature | EP Lab | November 11, 2019 | Hrishikesh Kadam
Cardiac rhythm management (CRM) devices in use today are evolving to raise the bar beyond monitoring and managing car
A comparison between the EPstar 2F and 6F catheters from Baylis. Electrophysiology catheters. EP lab

A comparison between the EPstar 2F and 6F catheters from Baylis.

News | EP Lab | October 31, 2019
October 31, 2019 — Baylis Medical announced the first North American use of its EPstar Fixed...
New Study Shows Chronic Epilepsy Associated With Marker of Cardiac Electrical Instability
News | EP Lab | October 24, 2019
LivaNova PLC announced the publication of a new study in Neurology, which suggests that chronic epilepsy may be...
Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
Overlay Init